Viscor syringes for injection contain higher concentrations of hyaluronic acid than other products on the market. Injecting intra-articular supplements containing hyaluronic acid is a well-known method in the treatment of osteoarthritis that is performed by a specialist doctor.



The isotonic solution in the syringe ready for injection Viscor contains hyaluronic acid, sodium chloride, monobasic sodium phosphate, dibasic sodium phosphate and injectable water.


Viscor is used to reduce pain and movement limitations in the joints caused by cartilage depletion as well as injuries caused by synovial fluid changes in large joints, including the knees and shoulders.


Intravenous injection of Viscor is absolutely contraindicated because it may cause systemic adverse effects.
Viscor is contraindicated in patients with the following conditions:
Patients with a history of allergies to sodium hyaluronate or its derivatives
- Patients with infections or skin diseases at the injection site
- Patients whose joint fluid is highly inflamed or infected
- Patients with systemic bleeding disorders


If the syringe is damaged or the blister is open, do not inject it separately.
If the product is stored in the refrigerator, bring the product to room temperature before injection.
Viscor is designed for single dose and single injection only; if the product is used twice, there is no guarantee that the drug will remain functional and sterile, and it may lead to injury and infection of the patient's joint.
Do not inject after the expiration date on the box or the Viscor syringe label.
Do not inject after the expiration date on the box or the Viscor syringe label.
Keep out of reach of children.

Side effects

In rare cases, whiskey injections may cause allergies, and in very rare cases, they may cause anaphylactic shock.
See your doctor or nurse immediately if you have any of the following symptoms:
- Skin lesions, itching
Swelling of the face, lips or tongue
Cough, shortness of breath
These side effects may occur both during and after the injection.
Symptoms such as pain, swelling, temporary inflammation, a feeling of warmth or redness in the treated joint may occur after intra-articular injection of Viscor. These symptoms are temporary and can be relieved by joint rest or cooling with ice packs. See your doctor if you do not have relief from any of these symptoms for up to 4 days or if you experience any of these symptoms.
People with autoimmune or connective tissue disorders are more likely to have side effects.

Use in specific populations

Children: Use the drug with caution as the safety of the drug in children has not been evaluated.
Pregnant women: Viscor's safety during pregnancy has not been proven and should be used with caution.
Breastfeeding women: Although the side effects of breastfeeding have not been proven, it is recommended to be used with caution during this period.

Amount and method of consumption

Viscor ready-to-inject syringes should only be injected once or twice by an experienced physician. Depending on the severity of the disease, several joints can be treated at the same time. Due to the molecular weight of hyaluronic acid in the syringe ready for Viscor injection, the beneficial effects of a full course of treatment may continue for the next 48 weeks. The treatment cycle may be repeated with your doctor's advice.

Packaging and storage conditions

A sterile injection syringe containing 50 mg of hyaluronic acid in a sterile package
Store below 30 ° C and protect from freezing.
Bring the product to room temperature before injection.

Hyaluronic acid is a complex carbohydrate that is one of the most important constituents of joint fluid. Hyaluronic acid in the joint has the property of viscoelasticity that causes the joints to lubricate. This substance is produced in the joints from type B synoviocytes. Hyaluronic acid deficiency causes complications such as osteoarthritis.
Osteoarthritis involves the breakdown of articular cartilage and eventually the involvement of subcutaneous bone, which causes inflammation of the surrounding tissues and reduced mobility of the joints. This complication may affect any of the joints. The most common joints involved are the knee, arm, pelvis and spine. Preventing osteoarthritis, especially in younger patients, is always the first step in delaying surgery.

Nikan Teb Kimia Company

As a knowledge-based pharmaceutical company, Nitka is focused on improving patients' lives by identifying, developing and commercializing new products. Our main goal is to produce products based on hyaluronic acid molecule for non-invasive orthopedic treatments.

  • This email address is being protected from spambots. You need JavaScript enabled to view it.

All logos and trademarks on this site are to manage the Nitkaco reserved